TSPO and myeloid sarcoma: The isoquinoline carboxamide 11C-(R)-PK11195, as well as second generation radiopharmaceuticals targeting the 18 kDa-translocator protein (TSPO) expressed on microglial cells, allow in vivo imaging of brain inflammation in a number of neurodegenerative and neuroinflammatory disorders, including MS [11–14].